USF-LVHN SELECT
The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma.
Publication/Presentation Date
8-1-2020
Abstract
INTRODUCTION: Mitogen-activated protein kinase (MAPK) signal transduction pathway inhibition through the use of agents binding to signal cascade kinases BRAF and MEK has become a key treatment strategy of patients with
AREAS COVERED: Detailed analysis is undertaken of the current data, presenting the efficacy and safety of recently developed therapies targeting BRAF and MEK inhibition in the setting of unresectable melanoma. MAPK signal transduction, translational findings, current phase I, II and III clinical trials, and ongoing studies are explored, including use of MAPK pathway inhibition in the neoadjuvant and adjuvant settings as well as in combination with immunotherapy and other therapies.
EXPERT OPINION: Inhibition of the MAPK pathway significantly improves response, progression-free survival, disease specific survival, and overall survival for patients with
Volume
20
Issue
8
First Page
687
Last Page
701
ISSN
1744-8328
Published In/Presented At
McClure, E., Carr, M. J., & Zager, J. S. (2020). The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. Expert review of anticancer therapy, 20(8), 687–701. https://doi.org/10.1080/14737140.2020.1796646
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
32667249
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article